Table 1.
ERβ and clinical outcome
| ERβ isoform | ERβ expression | ERα status | Number of patients | Clinical outcome | Year (Ref.) |
|---|---|---|---|---|---|
| ERβ | ↑ | – | 1400 | reduced RFS | 2018 [51] |
| ERβ | 32 | worse prognosis | 2017 [46] | ||
| ERβ | ↑ | +/− | 1026 | better prognosis | 2017 [30] |
| ERβ | ↑ | 120 | worse prognosis | 2017 [44] | |
| ERβ | – | 17 | no association with PFS | 2016 [52] | |
| ERβ | ↑ | + | 195 | reduced DFS; reduced DFS after endocrine therapy | 2016 [49] |
| Nuclear ERβ1 | – | 126 | no association with DFS and OS | 2015 [53] | |
| ERβ | ↑ | + | 127 | no association with PFS | 2015 [54] |
| ERβ | ↑ | – | 107 | reduced DFS | 2015 [54] |
| Nuclear ERβ1 | ↑ | – | 19 | reduced OS | 2015 [55] |
| ERβ1 | – | 571 | prolonged OS, DFS, and DMFS | 2015 [56] | |
| ERβ | ↑ | +/− | 583 | worse prognosis; worse endocrine therapy response | 2014 [48] |
| ERβ | ERα/ERβ: 1–1.5 | 78 | better hormonal treatment response | 2013 [45] | |
| ERβ | ↓ | 89 | reduced OS | 2012 [47] | |
| Nuclear ERβ1 | ↑ | +/− | 123 | better chemotherapy therapy and endocrine therapy response | 2011 [50] |
| Cytoplasmic ERβ 2/cx | +/− | 123 | poor chemotherapy response | 2011 [50] | |
| ERβ | ↓ | 41 | prolonged PFS; better aromatase inhibitor therapy response | 2010 [57] | |
| Nuclear P-S105-ERβ | ↑ | +/− | 459 | better prognosis | 2010 [58] |
RFS Recurrence-free survival, PFS Progression-free survival, DFS Disease-free survival, OS Overall survival, DMFS Distant metastases-free survival.